focus -WSS

focus

author：focus 2025-08-11 08:01:06 - browse：9

Feng Zhang Editas — Aera was formed to pursue a nanoparticle described by Feng Zhang in 2021. Susan Walsh/AP

Aera Therapeutics, a startup launched by the CRISPR pioneer Feng Zhang last year to solve one of the biggest bottlenecks in genetic medicine, has laid off a quarter of its staff, the company confirmed to STAT.

The layoffs come as the biotech market remains mired in a now nearly three-year-long downturn that has left startups struggling to attract both private and public funds. Aera attributed the layoffs to those headwinds and indicated it had axed a portion of the company dedicated to developing new gene-editing enzymes.

“In 2023, Aera launched to pursue an ambitious mission to develop transformative genetic medicines by harnessing enabling delivery technologies and precision payloads,” spokesman Dan Budwick said in a statement. “Although Aera remains in a strong cash position today, given the current biotech funding environment, we have chosen to take steps to focus our strategy and investments on the development of our novel delivery platforms, thereby further extending our cash runway.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Will generative AI in health care meet the fate of IBM's Dr. Watson?

knowledge

WSS

FDA's naming rule on biosimilars has undermined competition

Eliminate the waiting period for sterilization covered by Medicaid

Patient advocates debate FDA's accelerated approval process

RSV vaccines may be linked to small increased risk of developing GBS

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

RaDonda Vaught to speak at CommonSpirit event on patient safety

hotspot

focus

focus

New air purifier tech could be key to improving indoor air quality

Patient advocates debate FDA's accelerated approval process

Peter Hotez and the public health issue of online harassment

FDA's naming rule on biosimilars has undermined competition

23andMe had bad news about my health. I wish a person had delivered it

Change Healthcare cyberattack outage could last weeks

Virginia high school admissions case could be legal follow

How to address the problem of discarded donor organs

Virginia high school admissions case could be legal follow

Pfizer highlights cancer drugs it thinks could reignite investor interest

focus

Supreme Court mifepristone arguments center on docs' right to sue

Why getting cancer drugs just got harder for rural patients

Why getting cancer drugs just got harder for rural patients

Readout Newsletter: Merck, Vertex, and Viking updates

Food as medicine: Medically tailored meals may get standardized

Supreme Court mifepristone arguments center on docs' right to sue

focus

knowledge

leisure time

explore